Hormone-free option
Safety focused
Women’s Health Clinic FAQ
Can intimate polynucleotides treat severe vaginal dryness?
Intimate polynucleotides are non-hormonal biostimulatory treatments used in some clinics for vulvovaginal tissue quality. The important first step is confirming the symptom cause, not choosing an injectable by name.
Direct answer
Intimate polynucleotides may be discussed for severe vaginal dryness when tissue quality, GSM or vulvovaginal atrophy is part of the picture, often because PN/HA formulations aim to support hydration and repair signalling. Severe dryness still needs a diagnosis. It may be linked to menopause, cancer treatment, medication, infection, irritation or vulval skin disease. Moisturisers, lubricants, local vaginal ooestrogen and specialist review may all be relevant before deciding whether an injectable treatment is suitable.
Your clinician should review symptoms, medical history, allergies, medicines, cancer history where relevant, alternatives, expected benefits, limitations and aftercare before deciding whether treatment fits.
Educational only. Suitability must be confirmed after consultation and assessment. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether intimate polynucleotides are suitable.
Polynucleotides at a glance
Non-hormonal biostimulation
Active Ingredients
Highly purified DNA fragments, typically extracted from trout or salmon gonads.
Mechanism
Stimulates fibroblast cells to increase collagen and elastin production while drawing in moisture (hyaluronic acid synthesis).
Delivery Formats
Administered via topical vaginal creams, daily vaginal ovules, or in-clinic superficial injections.
Primary Uses
Reversing vaginal dryness, dyspareunia (painful sex), tissue laxity, and vulvovaginal irritation.
Important safety note
Biocompatibility: PNs possess a reported safety profile; they contain no immunogenic proteins and mimic human DNA, resulting in a very low risk of allergic reactions.
Allergy
Evidence
Aftercare
Alternatives
Detailed answer
Severe dryness needs diagnosis
Dryness may come from GSM, medication, cancer treatment, infection, irritants or vulval skin disease.
Hydration is one part of care
PN/HA may support tissue hydration, but moisturisers, lubricants and local ooestrogen may still be relevant.
Evidence
Symptoms
Alternatives
What it means
Ovule Efficacy: In a study using PN and hyaluronic acid ovules, 79% of women presenting with severe atrophy improved to mild or zero symptoms, and 21% achieved complete tissue restoration.
Why symptoms matter
Cream Efficacy: More than 60% of women using a PN-based vaginal cream reported meaningful symptom relief within the first two weeks.
Evidence limits
Evidence is encouraging in selected areas, but intimate-use claims should remain cautious and assessment-led.
Treatment fit
Treatment Costs should be confirmed on the /pricing/ page before booking
What this means in practice
Treatment Costs should be confirmed on the /pricing/ page before booking
Onset of Action: Symptom relief often begins within the first 2 to 3 weeks of initiating treatment.
Patient safety
Why diagnosis comes first
Many intimate symptoms overlap. The right treatment depends on whether the issue is GSM, infection, vulval skin disease, scarring, pelvic-floor guarding, medication effect or another cause.
It checks the cause
Ovule Efficacy: In a study using PN and hyaluronic acid ovules, 79% of women presenting with severe atrophy improved to mild or zero symptoms.
It protects safety
Biocompatibility: PNs possess a reported safety profile; they contain no immunogenic proteins and mimic human DNA, resulting in a very low risk of allergic.
It reviews alternatives
Moisturisers, lubricants, local ooestrogen, pelvic-floor care or specialist review may be more appropriate first.
It sets expectations
Polynucleotides are gradual tissue-support treatments, not instant resolves or promised outcomes.
Non-hormonal does not mean automatic
A hormone-free option may still be unsuitable if there is infection, unexplained bleeding, pregnancy, recent surgery, severe fish allergy or unclear pelvic pain.
Good care explains product source, treatment route, alternatives, limits, aftercare and when another medical pathway is safer.
Considerations
What to consider
Treatment planning should include diagnosis, symptom pattern, allergy risk, medicines, consent, realistic timelines and aftercare.
Consultation priorities
A consultation should review symptoms, medical history, fish allergy, infection risk, bleeding risk, pregnancy status, expectations and alternatives.
Consent
Aftercare
Review
Before treatment
Consultation: Begins with a comprehensive medical history review to rule out any contraindications and align expectations.
During care
Preparation: For injectables, a topical numbing cream is applied to the vulvovaginal area to ensure patient comfort.
Aftercare
The Procedure: The treatment takes approximately 30 to 45 minutes; the solution is administered via fine needles or a cannula directly into the superficial dermal layers.
When to reassess
If symptoms persist, worsen or do not match expectations, reassessment is safer than repeating treatment automatically.
Practical expectations
Onset of Action: Symptom relief often begins within the first 2 to 3 weeks of initiating treatment.
Costs and treatment plans should be confirmed before booking; do not rely on generic package claims.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: polynucleotides are fillers
Reality: they are biostimulatory DNA fragments used for gradual tissue-quality support, not instant volume.
Myth: hormone-free means suitable for everyone
Reality: fish allergy, infection, bleeding, pregnancy, recent surgery and unclear pain can make treatment unsuitable.
Myth: results are promised
Reality: response varies and should be reviewed before repeating treatment.
Evidence and limits
Mechanism-of-action language should not be treated as proof of a predictable result.
Alternatives still matter
Moisturisers, local hormonal care, pelvic-floor physiotherapy, infection treatment or specialist review may be better for some patients.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting an injectable treatment.
Are red flags absent?
Active infection, unexplained bleeding, severe pain or new vulval changes should be checked first.
Are alternatives clear?
Ask what conservative, hormonal, pelvic-floor or specialist options may be more appropriate.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when diagnosis is clear, goals are realistic, red flags are absent and aftercare is understood.
No red flags
Review plan
Reasons to pause
Pause treatment for active infection, unexplained bleeding, pregnancy, severe fish allergy, recent pelvic surgery, severe pain or changing vulval skin.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Allergy symptoms
Swelling of the lips, tongue or face, breathing difficulty, widespread hives, faintness or collapse needs urgent help.
Bleeding or new skin change
New post-menopausal bleeding, ulcers, changing white plaques, unusual discharge or visible blood in urine should be assessed.
Infection signs
Fever, pus, spreading redness, worsening swelling or feeling unwell after a procedure needs prompt advice.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
Regulatory resources
Authoritative resources
These sources support assessment-led, evidence-aware patient information and help separate clinical care from promotional claims.
NICE menopause recommendations
NICE supports assessment-led discussion of GSM, non-hormonal care and vaginal ooestrogen, including cancer-history nuance.
NHS information on vaginal ooestrogen
NHS patient guidance helps distinguish local vaginal ooestrogen from broader HRT discussions.
ACOG guidance on urogenital symptoms after ooestrogen-dependent breast cancer
This guidance supports shared decision-making and careful framing for cancer survivors with GSM symptoms.
Next step
Book a clinical consultation
A consultation can confirm whether intimate polynucleotides may be suitable, whether another pathway should come first, and what realistic outcomes, risks and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 51 imported records. Additional reviewed material included peer-reviewed clinical papers; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
